Renal cancer is one of the most common genitourinary carcers. However

25% patients present with locally invasive or metastatic renal cancer at the time of diagnosis

and one third of patients who received  esection of localized disease will have a recurrence or progression. Recently

immunotherapy for renal cancer has made significant progress. Especially

some immunotherapeutic agents (such as immune checkpoint inhibitor

tumor vaccine) have been proved to improve the prognosis of patients with metastatic renal cancer. In this review

the effects of immunotherapeutic agents in the treatment of renal cancer were summarized.